Lénaïg Tanneau, Ph.D.

Consultant

Portrait-of-Lenaig-Tanneau_Pharmetheus

Bio

  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes QTc modeling and pharmacometrics in therapeutic areas such as infectious diseases and oncology
  • Previously worked as pharmacometrician at Ipsen, France, as contract researcher at Uppsala University in collaboration with Merck KGaA, and as temporary MIDD Consultant at Pharmetheus, Sweden
  • M.Sc. in Pharmacokinetics (2014) from Paris Descartes University, France, Pharm.D. (2015) from University of Nantes, France, and Ph.D. in Pharmacometrics (2022) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Assessment of Phase 1 pharmacokinetic-pharmacodynamic predictions, based on Phase 3 clinical trials results. Depemokimab pharmacokinetics and response in blood eosinophil count reduction for asthma and chronic rhinosinusitis with nasal polyps patientsUse of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis